Literature DB >> 11978521

The role of pathologists in the quality control of diagnosis and treatment of rectal cancer-an overview.

I D Nagtegaal1, J H J M van Krieken.   

Abstract

Pathological examination of the rectal cancer resection specimen has an increasingly important role in influencing decisions about clinical management. Standardisation of the examination procedures and reporting are necessary. To evaluate the relevant pathological factors, data from randomised clinical trials with adequate follow-up are necessary. From a recently closed trial on the treatment of rectal cancer (preoperative radiotherapy or total mesorectal excision (TME) surgery alone?), the pathological data were used to evaluate the importance of pathological factors, like circumferential margin and tumour, lymph nodes, metastasis (TNM) stage. Furthermore, it was possible to evaluate the surgical procedures and correlate these findings to clinically relevant endpoints. In this review, we describe the standard evaluation of a rectal cancer specimen with special attention to preoperative irradiated specimens.

Entities:  

Mesh:

Year:  2002        PMID: 11978521     DOI: 10.1016/s0959-8049(02)00056-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  28 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Lymph node harvest in colon and rectal cancer: Current considerations.

Authors:  James R McDonald; Andrew G Renehan; Sarah T O'Dwyer; Najib Y Haboubi
Journal:  World J Gastrointest Surg       Date:  2012-01-27

3.  Colorectal Cancer OncoGuia: surgical pathology report guidelines.

Authors:  Xavier Sanjuán; Antonio Salas; Josep Lloreta; Paula Manchon Walsh
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

Review 4.  The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment.

Authors:  Jeremy R Parfitt; David K Driman
Journal:  J Clin Pathol       Date:  2006-10-17       Impact factor: 3.411

Review 5.  A Review of the Long-Term Oncologic Outcomes of Robotic Surgery Versus Laparoscopic Surgery for Colorectal Cancer.

Authors:  Fatima G Wilder; Atuhani Burnett; Joseph Oliver; Michael F Demyen; Ravi J Chokshi
Journal:  Indian J Surg       Date:  2015-10-22       Impact factor: 0.656

6.  Distribution of lymph nodes in the mesorectum: how deep is TME necessary?

Authors:  R O Perez; V E Seid; E H Bresciani; C Bresciani; I Proscurshim; D D Pereira; D Kruglensky; V Rawet; A Habr-Gama; D Kiss
Journal:  Tech Coloproctol       Date:  2008-05-30       Impact factor: 3.781

7.  [Pathological work-up of rectal cancer following partial/total mesorectal excision].

Authors:  K J Schmitz; C Chmelar; E Berg; K W Schmid
Journal:  Pathologe       Date:  2011-07       Impact factor: 1.011

8.  ¹⁸F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes.

Authors:  Felipe A Calvo; Claudio V Sole; Dolores de la Mata; Luis Cabezón; Marina Gómez-Espí; Emilio Alvarez; Paz Madariaga; José L Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-23       Impact factor: 9.236

9.  Tumor micrometastases in mesorectal lymph nodes and their clinical significance in patients with rectal caner.

Authors:  Yang-Chun Zheng; Yu-Ying Tang; Zong-Guang Zhou; Li Li; Tian-Cai Wang; Yi-Ling Deng; Dai-Yun Chen; Wei-Ping Liu
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

10.  Factors related to preoperative assessment of the circumferential resection margin and the extent of mesorectal invasion by magnetic resonance imaging in rectal cancer: a prospective comparison study.

Authors:  Young-Wan Kim; Seung-Whan Cha; Juyon Pyo; Nam-Kyu Kim; Byung-Soh Min; Myeong-Jin Kim; Hoguen Kim
Journal:  World J Surg       Date:  2009-09       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.